-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251

Benzinga·07/30/2026 19:10:08
Listen to the news
HC Wainwright & Co. analyst Andrew S. Fein maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $237 to $251.